Johnson & Johnson improved its 2021 guidance, leaving its forecast for revenue from the sale of its single-dose Covid-2,5 vaccine unchanged at $19 billion.
Going into detail, in the third quarter i revenues of the American pharmaceutical giant rose by 10,7% to 23,3 billion dollars, a result lower than the expectations of analysts who expected 23,8 billion in revenue. In the same period, the revenue from the sale of the vaccine have reached 502 million dollars, while adjusted earnings per share it came in at $2,60, up 18,2% and higher than market expectations which stopped at $2,35.
“Our third quarter results demonstrate solid performance driven by above-market results in the Pharmaceuticals business, continued recovery in the Medical Devices business and strong growth in the Consumer Health business,” said Alex Gorsky, president and chief executive officer.
As for 2021, Jonhson & Johnson has revised upwards forecasts for annual adjusted earnings, it climbed to $9,77-9,82 per share from the previous $9,60-9,70 per share. The group has also improved its outlook on turnover, moving from the previous guidance of between 93,8 billion and 94,6 billion to the new range included in the range between 94,1 and 94,6 billion. Kept unchanged a 2,5 billion the target on the sale of vaccines anti-Covid related to the whole of 2021.
In New York, a few minutes from the opening of the American Stock Exchange, the title J&J it gained 1,86% to $163,10 per share.
